What is the 13F Pro Quality Score for CNMD?

13F Pro ranks CONMED Corp (CNMD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CNMD's current score at https://13fpro.ai/research/CNMD (free sign-up required for the full ranking).

Which hedge funds own the most CNMD stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CNMD include BlackRock,, LINDEN ADVISORS, TENOR CAPITAL MANAGEMENT Co., L.P.. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/CNMD as soon as new 13F filings post.

Where does 13F Pro source CNMD data?

All CONMED Corp fundamentals and ownership data come directly from SEC EDGAR. CONMED Corp files with the SEC under CIK 816956. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CNMD in?

CONMED Corp (CNMD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CNMD research updated on 13F Pro?

CNMD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CONMED Corp(CNMD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 816956 CNMD stock profile & AI dashboard →

13F Pro Quality Score

56.5/100

Rank #1,094 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

48.2/100

Profitability

56.8/100

Balance Sheet

60.5/100

Earnings Quality

76.6/100

Free Cash Flow

67.4/100

Institutional Flow

45.5/100

Revenue Scale

54.3/100

Dilution Risk

40.8/100

CNMD Stock Analysis & AI Quality Score

AI stock analysis and institutional research for CONMED Corp (CNMD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CNMD at 56.5/100 on a 32-signal composite quality model, placing it at rank #1,094 of 2,879 stocks — the top half of the AI-ranked universe. CNMD scores in the top quartile across earnings quality (76.6). Shareholder dilution risk is elevated at 40.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q4 2025), CONMED Corp reports quarterly revenue of $373.2M, net income of $16.8M, an operating margin of 9.8%. Top institutional holders of CNMD by reported 13-F value include BlackRock,, LINDEN ADVISORS, TENOR CAPITAL MANAGEMENT Co., L.P., based on the most recent SEC filings. CNMD trades on the NYSE exchange and files with the SEC under CIK 816956. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CNMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CONMED Corp directly from SEC EDGAR. CONMED Corp's 13F Pro composite quality score has ranged between 8 and 67 since 2021, currently 56.5 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about CONMED Corp

Quirks, history, and lore behind CNMD — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · listed on Nasdaq · headquartered in upstate New York · sells into hospitals and surgical centers worldwide.
2
The Numbers
Annual revenue in the neighborhood of $1 billion — small-cap territory — with a global salesforce pushing products into over 100 countries.
3
The History
Founded in the 1970s, it grew steadily through acquisitions and carved out a niche in minimally invasive surgery long before that phrase was cool.
4
The Secret
Its product catalog spans electrosurgery, orthopedics, and endoscopy — essentially a one-stop shop for the surgeon who likes options and hates switching vendors.
5
The Lore
The company's name is a mashup of its founding philosophy: CONtinuous MEDical innovation — a corporate acronym that actually describes what it does, which is rarer than you'd think.
6
The Giveaway
Ticker CNMD, based in Utica, New York, making surgical and patient monitoring devices — this is the mid-cap medtech that quietly keeps operating rooms running.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q4 2025

$373.2M

Net Income

Q4 2025

$16.8M

Free Cash Flow

Q4 2025

$41.2M

Operating Margin

Q4 2025

9.8%

ROIC

Q4 2025

2.0%

D/E Ratio

Q4 2025

0.81

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+5.2% YoY

$1.37BFY 2025

FY22 $1.05BFY23 $1.24BFY24 $1.31BFY25 $1.37B

Net Income

-64.4% YoY

$47.1MFY 2025

FY22 $-80.6MFY23 $64.5MFY24 $132.4MFY25 $47.1M

Operating Income

-48.8% YoY

$102.6MFY 2025

FY22 $70.1MFY23 $120.6MFY24 $200.3MFY25 $102.6M

EPS (Diluted)

-64.5% YoY

$1.51FY 2025

FY22 $-2.68FY23 $2.04FY24 $4.25FY25 $1.51

Total Assets

+0.8% YoY

$2.33BFY 2025

FY22 $2.30BFY23 $2.30BFY24 $2.31BFY25 $2.33B

Total Debt

-7.8% YoY

$834.9MFY 2025

FY22 $1.05BFY23 $973.8MFY24 $905.8MFY25 $834.9M

Op. Cash Flow

+2.2% YoY

$170.7MFY 2025

FY22 $33.4MFY23 $125.3MFY24 $167.0MFY25 $170.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$1.37B +5.2%	$1.31B +5.0%	$1.24B +19.1%	$1.05B +3.4%	$1.01B +17.2%	$862.5M
Net Income	$47.1M -64.4%	$132.4M +105.4%	$64.5M +180.0%	$-80.6M -229.0%	$62.5M +556.7%	$9.5M
Operating Income	$102.6M -48.8%	$200.3M +66.1%	$120.6M +72.2%	$70.1M -36.2%	$109.7M +138.5%	$46.0M
EPS (Diluted)	$1.51 -64.5%	$4.25 +108.3%	$2.04 +176.1%	$-2.68 -238.1%	$1.94 +506.2%	$0.32
Total Assets	$2.33B +0.8%	$2.31B +0.3%	$2.30B +0.1%	$2.30B +30.1%	$1.77B +0.8%	$1.75B
Total Debt	$834.9M -7.8%	$905.8M -7.0%	$973.8M -7.7%	$1.05B +54.1%	$684.7M -9.2%	$753.6M
Operating Cash Flow	$170.7M +2.2%	$167.0M +33.2%	$125.3M +275.7%	$33.4M -70.1%	$111.8M +73.2%	$64.5M

AI Insight: CNMD Financial Trends

Revenue growth accelerated to 7.8% year-over-year in Q4 2025 despite volatile operating profitability throughout 2025.

• Revenue increased from $346M in Q4 2024 to $373M in Q4 2025, marking 7.8% year-over-year growth.

• Total debt declined from $991M in Q1 2024 to $835M in Q4 2025, reducing leverage by $156M.

• Equity strengthened from $855M in Q1 2024 to $1,033M in Q4 2025, improving by $178M.

⚠ Operating income dropped from $66M in Q3 2024 to just $12M in Q3 2025, showing significant profitability volatility.

⚠ Net income fell to $3M in Q3 2025 from $49M in Q3 2024, indicating margin pressure challenges.

AI Insight: CNMD Ratio Trends

CONMED's profitability collapsed in 2025 with operating margin falling from 20.8% in Q3 2024 to just 3.5% in Q3 2025.

• Operating margin plunged from 20.8% in Q3 2024 to 3.5% in Q3 2025, erasing prior gains.

• ROIC deteriorated from 14.0% in Q3 2024 to 2.5% in Q3 2025, indicating capital efficiency collapse.

• Debt-to-equity improved steadily from 1.16 in Q1 2024 to 0.81 in Q4 2025, strengthening balance sheet.

• Net profit margin declined from 15.5% peak in Q3 2024 to 0.9% in Q3 2025.

⚠ Q4 2025 showed sequential improvement with operating margin recovering to 9.8% from Q3's 3.5% trough.

⚠ ROA hit cycle low of 0.5% in Q3 2025, signaling severe asset utilization challenges.

Get alerted when CNMD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CONMED Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CNMD

BlackRock, Inc.
$170.6M4,825,173 sh
LINDEN ADVISORS LP
$135.2M139,220,000 sh
TENOR CAPITAL MANAGEMENT Co., L.P.
$122.4M125,020,000 sh
Context Capital Management, LLC
$115.9M119,429,000 sh
EARNEST PARTNERS LLC
$90.9M2,569,653 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$73.4M2,076,417 sh
CAMDEN ASSET MANAGEMENT L P /CA
$67.1M69,300,000 sh
FULLER & THALER ASSET MANAGEMENT, INC.
$58.1M1,641,766 sh
CAPSTONE INVESTMENT ADVISORS, LLC
$51.0M52,500,000 sh
BANK OF AMERICA CORP /DE/
$49.6M1,402,620 sh

Fund	Value	Shares
BlackRock, Inc.	$170.6M	4,825,173
LINDEN ADVISORS LP	$135.2M	139,220,000
TENOR CAPITAL MANAGEMENT Co., L.P.	$122.4M	125,020,000
Context Capital Management, LLC	$115.9M	119,429,000
EARNEST PARTNERS LLC	$90.9M	2,569,653
VANGUARD PORTFOLIO MANAGEMENT LLC	$73.4M	2,076,417
CAMDEN ASSET MANAGEMENT L P /CA	$67.1M	69,300,000
FULLER & THALER ASSET MANAGEMENT, INC.	$58.1M	1,641,766
CAPSTONE INVESTMENT ADVISORS, LLC	$51.0M	52,500,000
BANK OF AMERICA CORP /DE/	$49.6M	1,402,620

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CNMD on your watchlist

Track score changes the day CONMED Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CNMD a good stock to buy?

13F Pro's AI-powered analysis of CONMED Corp (CNMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CNMD are available on the CNMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CNMD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CNMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CONMED Corp's investment landscape.